-
Mashup Score: 7Cellular Therapies and Novel Targeted Agents Will Shape the Future of R/R ALL Management - 7 hour(s) ago
Marlise Luskin, MD, MSCE, discusses the treatment paradigm for relapsed/refractory ALL and research seeking to integrate agents into the frontline setting
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 5Cellular Therapies and Novel Targeted Agents Will Shape the Future of R/R ALL Management - 16 day(s) ago
Marlise Luskin, MD, MSCE, discusses the treatment paradigm for relapsed/refractory ALL and research seeking to integrate agents into the frontline setting
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Cellular Therapies and Novel Targeted Agents Will Shape the Future of R/R #ALL Management @LuskinMarlise @DanaFarber https://t.co/BOCcLbMUFW
-
-
Mashup Score: 5Cellular Therapies and Novel Targeted Agents Will Shape the Future of R/R ALL Management - 18 day(s) ago
Marlise Luskin, MD, MSCE, discusses the treatment paradigm for relapsed/refractory ALL and research seeking to integrate agents into the frontline setting
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Cellular Therapies and Novel Targeted Agents Will Shape the Future of R/R #ALL Management @LuskinMarlise @DanaFarber https://t.co/BOCcLbMUFW
-
-
Mashup Score: 1Study Evaluates Mini-Hyper-CVD Plus Inotuzumab, Dose-Dense Blinatumomab for ALL | Blood Cancers Today - 3 month(s) ago
The one-year overall survival rate of 90% was higher than the 66% seen with historical mini-hyperCVD plus inotuzumab ozogamicin with sequential blinatumomab.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
A phase II trial led by Elias Jabbour, MD, of @MDAndersonNews, evaluated mini-hyper-CVD plus inotuzumab ozogamicin and early, dose-dense blinatumomab for relapsed or refractory B-cell #ALL. 📰 Read more: https://t.co/iuTzTactJK https://t.co/Q7tr4b8Ckj
-
-
Mashup Score: 11
An abstract is unavailable.
Source: journals.lww.comCategories: General Medicine News, Oncologists1Tweet-
The right treatment for relapsed/refractory #ALL is CAR T-cell therapy, said Jae H. Park, MD, at @MSKCancerCenter, at the 2024 Great Debates & Updates in Hematologic Malignancies meeting. https://t.co/4xXSQ4xEtR https://t.co/0OGJUwIDrK
-
-
Mashup Score: 11
An abstract is unavailable.
Source: journals.lww.comCategories: General Medicine News, Oncologists1Tweet-
The right treatment for relapsed/refractory #ALL is CAR T-cell therapy, said Jae H. Park, MD, at @MSKCancerCenter, at the 2024 Great Debates & Updates in Hematologic Malignancies meeting. https://t.co/4xXSQ4xEtR https://t.co/0OGJUwIDrK
-
-
Mashup Score: 11
An abstract is unavailable.
Source: journals.lww.comCategories: General Medicine News, Oncologists1Tweet-
The right treatment for relapsed/refractory #ALL is CAR T-cell therapy, said Jae H. Park, MD, at @MSKCancerCenter, at the 2024 Great Debates & Updates in Hematologic Malignancies meeting. https://t.co/4xXSQ4xEtR https://t.co/0OGJUwIDrK
-
-
Mashup Score: 1Blinatumomab Plus Consolidation May Be ‘New Standard of Care’ in B-ALL | Blood Cancers Today - 7 month(s) ago
Adding blinatumomab to consolidation chemotherapy led to improved survival in MRD-negative patients with newly diagnosed B-lineage ALL.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
@US_FDA @Amgen @AmgenOncology Read more about the E1910 trial, by @MRLitzow of @MayoClinic and colleagues, that led to the approval of blinatumomab for B-Cell #ALL. 📚 https://t.co/mRIth6oRjG https://t.co/wVhtntMEGc
-
-
Mashup Score: 1
The US FDA approved blinatumomab for the treatment of CD19-positive, Philadelphia chromosome-negative B-cell precursor ALL.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet-
🎉 The @US_FDA has approved blinatumomab for the treatment of adult and pediatric B-Cell #ALL, according to a press release from @Amgen/@AmgenOncology. 📰 Read more: https://t.co/Ne8hoZcyUP https://t.co/q0LLyYW2Rn
-
-
Mashup Score: 1
The major challenges for clinicians treating older patients with acute lymphoblastic leukemia surround the emergence of resistance to existing therapies and the toxicities associated with current chemotherapies.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet-
While most common in children, about half of #ALL cases arise in adults. Survival rates vary: over 90% for children under 15, 70-80% for adolescents/young adults, but drop for those 60+, with less than 20% survival at 3 years, & less than 10% over 75. https://t.co/d5SRAABoid
-
Cellular Therapies and Novel Targeted Agents Will Shape the Future of R/R #ALL Management @LuskinMarlise @DanaFarber https://t.co/BOCcLbMUFW